Skip to main content
SpringerLink
Log in

Can high bone turnover markers identify osteopenic postmenopausal women at risk of future fracture?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bauer DC et al. (2006) Pretreatment levels of bone turnover and the anti-fracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 21: 292–299

    Article  CAS  Google Scholar 

  2. Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077–2082

    Article  CAS  Google Scholar 

  3. McClung MR et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333–340

    Article  CAS  Google Scholar 

  4. Chesnut CH III et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249

    Article  CAS  Google Scholar 

  5. McCloskey EV et al. (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22: 135–141

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice. DM Reid is grateful to the UK Arthritis Research Campaign for continued infra-structure support.

Author information

Author notes

  1. University of Aberdeen, Medical School, Foresterhill, Aberdeen AB25 2ZD, UK d.m.reid@abdn.ac.uk

Authors and Affiliations

  1. DM Reid is Professor of Rheumatology and Head of the Department of Medicine and Therapeutics, University of Aberdeen, UK.,

    David M Reid

Authors
  1. David M Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

GlaxoSmithKline: consultant, speakers bureau and research support; Merck: speakers bureau; Procter and Gamble: consultant; Roche: consultant, speakers bureau and research support.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, D. Can high bone turnover markers identify osteopenic postmenopausal women at risk of future fracture?. Nat Rev Endocrinol 3, 570–571 (2007). https://doi.org/10.1038/ncpendmet0560

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0560

  • Springer Nature Limited

This article is cited by

Search

Navigation